Study of Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of LNP023 in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Active, not recruiting
Novartis Pharmaceuticals
Phase 2
The main purpose of this study is to evaluate the efficacy of LNP023 in patients with PNH,
showing signs of active hemolysis despite treatment with SoC (defined as an antibody with
anti C5 activity).
Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted
Completed
Novartis Pharmaceuticals
Phase 2
The study is an open-label, two cohort non-randomized study evaluating the efficacy, safety,
and pharmacokinetics of LNP023 in patients with C3G (Cohort A) and patients who have
undergone kidney transplant and have C3G recurrence (Cohort B).
Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy
Recruiting
Novartis Pharmaceuticals
Phase 2
This is a randomized, open-label, two arm, parallel group, proof-of-concept, non-confirmatory
study evaluating the efficacy and safety of LNP023 compared with rituximab in subjects with
membranous nephropathy (MN) who are at high risk of disease progression defined on the basis
of antibody anti-PLA2R titre and proteinuria.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
